Trial Profile
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2015
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Apr 2014 New trial record
- 10 Sep 2010